Target
Caspase-2
Novel target differentiated from NASH competitors
- Activation drives lipogenesis and steatohepatitis
- Induced by ER stress and TNF
- Proteolytic activation of S1P and activation of SREBP
- Inhibition halts progression of NASH
- Therapeutics against caspase-2 can be used to prevent and treat stress-driven fatty liver diseases
- SBDD and biologic technologies can be applied
![caspase2-img-left](https://elgiatherapeutics.com/wp-content/uploads/2020/12/caspase2-img-left.jpg)
![caspase2-img-right](https://elgiatherapeutics.com/wp-content/uploads/2020/12/caspase2-img-right.jpg)